Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Income Statement

v3.7.0.1
Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Revenues $ 0 $ 0 $ 0 $ 0
Operating expenses:        
Research and development 515 105 1,199 120
General and administrative 800 618 1,649 923
Depreciation 5 1 8 1
Total operating expenses 1,320 724 2,856 1,044
Loss from operations (1,320) (724) (2,856) (1,044)
Other income (expense):        
Loss from change in fair value of warrant liability (3,342) 0 (2,283) 0
Gain from settlement of liability 0 0 149 0
Gain from expiration of warrants 1,238 0 1,238 0
Other expense 0 0 (1) 0
Interest expense 0 (15) (1) (27)
Net loss $ (3,424) $ (739) $ (3,754) $ (1,071)
Net loss per common share - basic and diluted $ (0.19) $ (0.08) $ (0.23) $ (0.14)
Weighted average common shares outstanding - basic and diluted 17,863,707 8,875,173 16,137,312 7,796,782

Source